Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [The Battery Metal Nobody Told You About]( [See why investors are taking a hard look at vanadium right now.]( --------------------------------------------------------------- December 20, 2023 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?]( little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming. [See what this potential vanadium hotspot could mean to investors.]( --------------------------------------------------------------- [Caterpillar]( Ticker: [CAT]( Recent Price: $292.96 Average Analyst Price Target: $272.80 (-5.03%) Market Cap: $145.45B Role Transaction Description No. of Shares Amount Date Chairman & CEO, Director Informative Buy Non Open Market Buy 422,260 $59,942,080 2 Days Ago Recent Analyst Action: Stanley Elliott, analyst at Stifel Nicolaus, reiterates coverage on [Caterpillar (CAT)]( in the Industrials sector with a Buy rating and a price target of $293 (22 hours ago). Here are 3rd party ratings for [CAT](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Bottom 4% (242 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [ChatGPT, iOS and the Better AI Play...]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- [Verrica Pharmaceuticals]( Ticker: [VRCA]( Recent Price: $5.56 Average Analyst Price Target: $11.80 (120.32%) Market Cap: $233.88M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 1,233,931 $6,941,716 2 Days Ago Recent Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on [Verrica Pharmaceuticals (VRCA)]( in the Healthcare sector with a Buy rating and a price target of $12 (4 weeks ago). Here are 3rd party ratings for [VRCA](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 30% (76 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Perspective Therapeutics]( Ticker: [CATX]( Recent Price: $0.34 Average Analyst Price Target: $1.35 (299.76%) Market Cap: $72.67M Role Transaction Description No. of Shares Amount Date CMO Informative Buy Non Open Market Buy 595,425 $186,206 2 Days Ago Director Informative Buy Non Open Market Buy 23,680 $6,978 2 Days Ago CFO Informative Buy Non Open Market Buy 125,000 $31,250 2 Days Ago Director Informative Buy Non Open Market Buy 185,200 $48,474 3 Days Ago Recent Analyst Action: Justin Walsh, analyst at JonesTrading, reiterates coverage on [Perspective Therapeutics (CATX)]( in the Healthcare sector with a Buy rating and a price target of $1.5 (1 day ago). Here are 3rd party ratings for [CATX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 30% (76 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Biggest Drug Ever]( Morgan Stanley predicts it will become the biggest selling drug of all time. The Wall Street Journal calls it "King Kong"... Barron's says it will be a "blockbuster"... And The New York Post calls it "game-changing"... [Get the name of the drug here ]( --------------------------------------------------------------- [Cadence Design]( Ticker: [CDNS]( Recent Price: $274.33 Average Analyst Price Target: $271.75 (-1.43%) Market Cap: $74.41B Role Transaction Description No. of Shares Amount Date Director Informative Buy Options Exercised and fully kept 10,000 $138,100 2 Days Ago Recent Analyst Action: Vivek Arya, analyst at Bank of America Securities, reiterates coverage on [Cadence Design (CDNS)]( in the Technology sector with a Buy rating and a price target of $315 (4 days ago). Here are 3rd party ratings for [CDNS](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 36% (91 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Amylyx Pharmaceuticals Inc]( Ticker: [AMLX]( Recent Price: $13.98 Average Analyst Price Target: $41.20 (177.75%) Market Cap: $958.08M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 4,000 $59,880 2 Days Ago Recent Analyst Action: Neena Bitritto-Garg, analyst at Deutsche Bank, reiterates coverage on [Amylyx Pharmaceuticals Inc (AMLX)]( in the Healthcare sector with a Buy rating and a price target of $36 (1 week ago). Here are 3rd party ratings for [AMLX](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 30% (76 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"]( The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. [Get the name of the stock here ]( --------------------------------------------------------------- [First Merchants]( Ticker: [FRME]( Recent Price: $37.23 Average Analyst Price Target: $36.00 (-3.30%) Market Cap: $2.18B Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 1,380 $50,204 2 Days Ago Recent Analyst Action: Nathan Race, analyst at Piper Sandler, reiterates coverage on [First Merchants (FRME)]( in the Financial sector with a Buy rating and a price target of $36 (1 month ago). Here are 3rd party ratings for [FRME](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 27% (69 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Cardiff Oncology]( Ticker: [CRDF]( Recent Price: $1.36 Average Analyst Price Target: $7.33 (438.97%) Market Cap: $60.31M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 30,000 $41,100 2 Days Ago Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Cardiff Oncology (CRDF)]( in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). Here are 3rd party ratings for [CRDF](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Buy, Top 24% (61 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software